Palvella Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	5.94	3.08	4.16
Research & Development	8.15	8.79	13.88
Operating Expenses	14.1	11.87	18.04
Operating Income	-14.1	-11.87	-18.04
Interest Expense	-4.32	-	-10.36
Interest & Investment Income	-	6.27	-
Other Non Operating Income (Expenses)	-0.12	1.2	-0.17
EBT Excluding Unusual Items	-18.53	-4.41	-28.58
Other Unusual Items	1.1	23.1	-
Pretax Income	-17.43	18.69	-28.58
Income Tax Expense	-	-	-1.03
Net Income	-17.43	18.69	-27.55
Preferred Dividends & Other Adjustments	-	14.81	-
Net Income to Common	-17.43	3.88	-27.55
Shares Outstanding (Basic)	2	2	6
Shares Outstanding (Diluted)	2	2	6
Shares Change (YoY)	24.08%	-68.63%	-
EPS (Basic)	-7.83	2.19	-4.82
EPS (Diluted)	-7.83	2.17	-4.82
EBIT	-14.1	-11.87	-18.04

Updated Dec 16, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q